Melody(R) Transcatheter Valve Demonstrates Encouraging Results In Study On Patients With Congenital Heart Disease

Clinical trial results published in this week's Journal of the American College of Cardiology (JACC) describe six-month outcomes for patients using the Melody® Transcatheter Pulmonary Valve from Medtronic, Inc. (NYSE: MDT). The valve is implanted through a catheter procedure instead of open-heart surgery in patients with congenital heart disease affecting the function of their pulmonary valve. The first-of-its kind device is currently under review by the U.S.